Tested antivascular drug plus chemo versus chemo alone for TNBC
Part of Cancer, Skin clinical trials.
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70
- Your performance status is 0 or 1 (you can do daily activities with little or no help)
- Your breast cancer is triple-negative (no HER2, ER, or progesterone receptor) and is classified as a BLIS subtype by the study center
- Your cancer is stage IIA to IIIC and has not spread (pT1-3, N1-3, M0), and you already had surgery
- Your incision is fully healed before starting study treatment
- Your blood tests and organ function are “adequate” based on lab results done within 28 days before the first dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.